摘要
目的 探讨文拉法辛缓释片治疗广泛性焦虑障碍的临床效果和社会功能康复状况.方法 将75例广泛性焦虑障碍患者随机分为两组,研究组38例,口服文拉法辛缓释片治疗,对照组37例,口服劳拉西泮治疗,观察8周.于治疗前及治疗1周、2周、4周、8周末采用汉密顿焦虑量表、社会功能缺陷筛选量表、副反应量表评定临床疗效和不良反应.结果 治疗后两组汉密顿焦虑量表、社会功能缺陷筛选量表总分均较治疗前有显著下降（P＜0.01）;治疗1周、2周末对照组汉密顿焦虑量表评分较研究组下降更显著（P＜0.01）;治疗4周、8周末,研究组汉密顿焦虑量表、社会功能缺陷筛选量表评分较对照组下降更显著（P＜0.01）.治疗8周末研究组有效率92.11%,对照组为89.19%,两组差异无显著性（P＞0.05）.研究组不良反应发生率为23.63%,对照组为64.85%,研究组显著低于对照组（χ2=12.902,P＜0.01）.结论文拉法辛治疗广泛性焦虑障碍中远期疗效优于劳拉西泮,安全性高,依从性好,改善社会功能效果显著,可作为治疗广泛性焦虑障碍的一线药物在临床推广应用.
Objective To explore the clinical efficacy and social function rehabilitation of venlafaxine extended-release tablets in generalized anxiety disorder （GAD）. Methods Seventy-five GAD patients were randomly assigned to research group （n=38） took orally venlafaxine extended-release tablets and control group （n=37） did lorazepam for 8 weeks. Before treatment and at the end of the 1st, 2nd, 4th and 8th week, clinical efficacies were assessed with the Hamilton Anxiety Scale （HAMA） and Social Disabilitry Screening Schedule （SDSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS）. Results After treatment, the HAMA and SDSS total scores of both groups lowered more significantly compared with pretreatment （P〈 0.01） ; the HAMA scores at the end of the 1st and 2nd week lowered more significantly in the research than in the control group （P〈0.01） ; the HAMA and SDSS scores at the end of the 4th and 8th week lowered more significantly in the research than in the control group （P〈0.01）. At the end of the 8th week, effective rates were respectively 92.11% in the research and 89. 19% in the control group, which showed no significant difference （P〉0.05）. Incidences of adverse reactions were respectively 23.63% in the research and 64. 85% in the control group, the former were significantly lower than the latter （22 -12. 902, P〈 0.01）. Conclusion Venlafaxine has advantages over lorazepam in medium-and long-term results, safety and compliance, improves social function notably, and could be used as first-line drug.
出处
《临床心身疾病杂志》
CAS
2011年第4期310-312,共3页
Journal of Clinical Psychosomatic Diseases
